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Abstract
CD69 is a transmembrane lectin that can be expressed on most hematopoietic cells. In monocytes, it has been functionally
linked to the 5-lipoxygenase pathway in which the leukotrienes, a class of highly potent inflammatory mediators, are
produced. However, regarding CD69 gene expression and its regulatory mechanisms in monocytes, only scarce data are
available. Here, we report that CD69 mRNA expression, analogous to that of 5-lipoxygenase, is induced by the physiologic
stimuli transforming growth factor-b (TGF-b) and 1a,25-dihydroxyvitamin D3 (1a,25(OH)2D3) in monocytic cells. Comparison
with T- and B-cell lines showed that the effect was specific for monocytes. CD69 expression levels were increased in a
concentration-dependent manner, and kinetic analysis revealed a rapid onset of mRNA expression, indicating that CD69 is a
primary TGF-b/1a,25(OH)2D3 target gene. PCR analysis of different regions of the CD69 mRNA revealed that de novo
transcription was initiated and proximal and distal parts were induced concomitantly. In common with 5-lipoxygenase, no
activation of 0.7 kb or ,2.3 kb promoter fragments by TGF-b and 1a,25(OH)2D3 could be observed in transient reporter
assays for CD69. Analysis of mRNA stability using a transcription inhibitor and a 39UTR reporter construct showed that TGF-b
and 1a,25(OH)2D3 do not influence CD69 mRNA stability. Functional knockdown of Smad3 clearly demonstrated that
upregulation of CD69 mRNA, in contrast to 5-LO, depends on Smad3. Comparative studies with different inhibitors for
mitogen activated protein kinases (MAPKs) revealed that MAPK signalling is involved in CD69 gene regulation, whereas 5-
lipoxygenase gene expression was only partly affected. Mechanistically, we found evidence that CD69 gene upregulation
depends on TAK1-mediated p38 activation. In summary, our data indicate that CD69 gene expression, conforming with 5-
lipoxygenase, is regulated monocyte-specifically by the physiologic stimuli TGF-b and 1a,25(OH)2D3 on mRNA level,
although different mechanisms account for the upregulation of each gene.
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Introduction
The transmembrane lectin CD69 is best characterized and
widely used as an early T-lymphocyte activation marker that is
expressed upon inflammatory stimuli [1]. A major function of
CD69 is to shut down lymphocyte egress from lymphoid organs
via inhibition of sphingosine 1-phosphate signalling [2]. However,
CD69 expression has not only been found on lymphocytes, but on
all bone marrow-derived cells except erythrocytes (reviewed in
[1]). Regarding its expression on monocytic cells, one report exists
that describes constitutive expression on CD14 positive monocytes
[3], but in a subsequent study only 10% of total monocytes were
found to be positive for CD69. In that study the basal level of
CD69 was enhanced by stimulation with leptin, lipopolysaccharide
or phorbol 12-myristate 13-acetate (PMA) [4].
With respect to its role in monocytes, CD69 has been
functionally linked to 5-lipoxygenase (5-LO), the key enzyme in
the conversion of arachidonic acid to leukotrienes [3]. Leukotri-
enes are potent lipid mediators involved in inflammatory
disorders, including asthma, arthritis as well as allergic reactions,
and have been implicated in the pathogenesis of atherosclerosis
and different neoplasms [5]. Cross-linking of CD69 on monocytes
coincided with Ca
2+ influx, arachidonic acid release and
leukotriene B4 production [3]. Moreover, induction of apoptosis
by anti-CD69 antibodies in LPS-stimulated human monocytes or
monocytic THP-1 could be blocked by 5-LO inhibitors [6]. 5-
lipoxygenase is a known TGF-b/1a,25(OH)2D3 target gene in
monocytes [7,8], and several other genes are established to be
regulated by this combination of chemically unrelated mediators
[9]. The signalling pathways of TGF-b and 1a,25(OH)2D3 alone
are well understood, respectively. The lipophilic hormone
1a,25(OH)2D3 acts on mRNA expression via its nuclear receptor,
the vitamin D receptor (VDR). Together with its heterodimeric
binding partner, the retinoid X receptor (RXR), VDR binds to
vitamin D responsive elements (VDREs) in regulatory DNA
regions. Upon ligand binding, a complex of coactivator proteins is
recruited, which subsequently acts on the basal transcription
machinery [10]. On the other hand, the cell-impermeant peptide
TGF-b signals through a specific cell surface receptor, the TGF-b
receptor complex. Activation regulates mRNA biosynthesis either
via the canonical Smad transcription factor pathway [11], or via
non-Smad signalling pathways in which TGF-b activated kinase 1
(TAK1) is a central component and other mitogen activated
protein kinases (MAPKs) like p38, Jnk and Erk are major players
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on the DNA in cooperation with other transcription factors, where
the complexes interact with the basal transcription machinery,
whereas the signals of the non-Smad pathways are channelled
through specific transcription factors that receive the signals of the
different kinases. TGF-b and 1a,25(OH)2D3 share common effects
on cell growth and differentiation, but the exact mechanisms of
their interaction still remain to be elucidated.
Regarding mechanisms of CD69 gene regulation in monocytes,
no systematic studies are available to date. We report here that
CD69 is a novel TGF-b/1a,25(OH)2D3 target gene that is cell
type specifically regulated in monocytic cells, but exhibits
differences in the profile and the underlying mechanisms of gene
regulation as compared to 5-LO. The main distinctions are that
CD69 gene regulation by TGFb/1a,25(OH)2D3, in contrast to 5-
LO, depends on Smad3 and seems to be regulated by a signalling
axis involving TAK1-mediated p38 activation.
Materials and Methods
Plasmid constructs
The following plasmids were generated by PCR amplification of
the corresponding genomic regions from cDNA or genomic DNA
(both generated from THP-1 cells), double digest and subsequent
insertion into the respective parental vectors using standard
cloning procedures: pcDNA-CD69, pcDNA-CD69 Intron 1,
pcDNA-CD69 Exon 1–Intron 1, pcDNA-B2M, pGL3-CD69
0.650 and pGL3-CD69 2.26. In order to obtain plasmid pGL3-
Prom CD69 3UTR, the 39 end of the luciferase coding sequence
was removed from the parental vector by double digest and
reinserted as a PCR fragment, including an additional restriction
site, together with the CD69 39UTR PCR fragment. The PCR
primer sequences, parental vectors and restriction sites used for
insertion are summarized in Table 1. Plasmid pcDNA3.1-5LO
[14] was a kind gift of Dr. O. Ra ˚dmark (Stockholm, Sweden).
Reporter constructs p3TP-Lux [15], pGL3-basic-(CAGA)12MLP-
luc [16], p(DR3)4 tk luc [17] were kindly provided by Dr. J.
Massague ´ (New York, USA), Dr. C.-H. Heldin (Uppsala, Sweden)
and Dr. C. Carlberg (Luxembourg), respectively. Vectors pSG5
VDR and pSG5 RXR [18], were a kind gift of Dr. C. Carlberg
(Luxembourg), plasmids pCGN-Smad3 and pCGN-Smad4 [19]
were kindly provided by Dr. X. F. Wang (Durham, USA).
Cells and cell culture
The cell lines used in the study were obtained from DSMZ
(Deutsche Sammlung von Mikroorganismen und Zellkulturen,
Braunschweig, Germany). Mono Mac 6 cells (human acute
monocytic leukemia) were maintained in RPMI 1640 medium
supplemented with 10% (v/v) fetal calf serum, streptomycin
(100 mg/ml), penicillin (100 U/ml), 16non-essential amino acids,
oxaloacetic acid (1 mM) and insulin (10 mg/ml). THP-1 (human
acute monocytic leukemia), Jurkat (human T-cell leukemia),
MOLT-4 (human T-cell leukemia) and Rec-1 (human B cell
lymphoma) were maintained in RPMI 1640 medium supplement-
ed with 10% (v/v) fetal calf serum, streptomycin (100 mg/ml) and
penicillin (100 U/ml). HeLa (human cervix carcinoma) and 293T
(human embryonic kidney) cells were cultured in Dulbecco’s
modified Eagle’s medium supplemented with 10% (v/v) fetal calf
serum, streptomycin (100 mg/ml), penicillin (100 U/ml) and
sodium pyruvate (1 mM). The cells were grown in 100% humidity
at 37uC, 5% CO2 for routine culture and at 6% CO2 for
experimental use. For all experiments except luciferase assays, cells
were cultured in medium containing charcoal-stripped FCS for
24 h prior to specific treatment.
Real-time PCR (RT-qPCR)
Total RNA was extracted from the cells using TRIzol reagentH
(Life Technologies) following the manufacturer’s instructions, with
some modifications: Cell pellets were lysed with TRIzol reagent
using a 1 ml syringe with a 20 G Sterican hypodermic needle
(Braun, Germany) and incubated at room temperature for
10 minutes. Then, 200 ml chloroform were added, samples were
vortexed, incubated at room temperature for 15 minutes and
centrifuged at 15000 g, 45 min, at 4uC. Clear supernatant (450 ml)
was transferred into a new tube and 5 ml 3 M sodium acetate
pH 6.5 and 500 ml isopropanol were added. After vortexing, RNA
was allowed to precipitate for 3 h at –20uC. Samples were
centrifuged 1 h at 15000 g, 4uC. RNA pellets were washed with
1 ml 75% ethanol and centrifuged 1 h at 15000 g, 4uC.
Supernatants were removed and pellets were allowed to dry for
a few minutes and dissolved in 50 ml DEPC-treated water (55uC,
10 min). RNA was quantified spectrophotometrically at 260 nm
using a NanoPhotometerH (Implen, Munich, Germany). RNA
integrity was verified by agarose gel electrophoresis. Subsequently,
RNA was treated with DNaseI (Fermentas) to eliminate genomic
DNA contamination. For cDNA synthesis, a constant amount of
total RNA (2 mg) was reversely transcribed using the High
Capacity RNA-to-cDNA Kit (Applied Biosystems) following the
manufacturer’s instructions. Absolute quantities (expressed as
mRNA copies of the target gene per 10
6 mRNA copies of the
reference gene) were calculated from standard curves constructed
from serial dilutions of linearized plasmids, which contained
100 ng/ml yeast tRNA as carrier. Data for standards and
corresponding samples were always generated in the same PCR
run. Standard plasmids were: pcDNA-CD69 (encoding full-length
human CD69 cDNA), pcDNA Exon 1-Intron 1 and pcDNA
Intron 1 (containing parts of the CD69 gene) pcDNA-B2M
(containing parts of the human B2M coding sequence),
pcDNA3.1-5LO (encoding full-length human 5-lipoxygenase),
pCGN-Smad3 (encoding full-length human Smad3). B2M was
chosen as reference gene after it had been determined as the most
stable reference gene out of 5 candidates (b-actin, B2M, UBC,
GAPDH, HPRT1) using geNorm software on datasets generated
from THP1 and Mono Mac 6 cells that were treated with or
without TGFb/1a,25(OH)2D3. B2M mRNA levels remained
unchanged upon TGFb/1a,25(OH)2D3 or PMA treatment (data
not shown). Primer pairs used for qPCR are listed in Table 2.
Luciferase assays
For luciferase assays, HeLa cells were transfected with reporter
plasmids pGL3-CD69 0.650 (containing a 731 bp CD69 promoter
fragment in front of the luciferase gene), pGL3-CD69 2.26
(2340 bp CD69 promoter fragment 59 of luciferase), pGL3-Prom
CD69 3UTR (CD69 39UTR after the luciferase gene), p3TP-Lux
(promoter with adjacent SBEs and TREs 59 of luciferase), pGL3-
basic-(CAGA)12MLP-luc (promoter with 12 concatemerized SBEs
59 of luciferase), p(DR3)4 tk (promoter with four concatemerized
VDREs 59of luciferase) and pGL3-Basic (Promega, promoterless
control) and pGL3-Promoter (Promega, control in assays with
pGL3-Prom CD69 3UTR). Plasmid pRL-SV40 (Promega) was
used as internal normalization control in all transfections. In
settings where transcription factors were overexpressed during the
assay, vectors pSG5 VDR (encoding human VDR), pSG5 RXR
(encoding human RXR) and pCGN-Smad3 as well as pCGN-
Smad4 (encoding human Smad3 and Smad4, respectively) were
co-transfected. In corresponding control experiments, the respec-
tive empty vectors were transfected in equivalent amounts. One
day prior to transfection, cells were seeded in 24-well plates and
were transfected using the calcium phosphate method. After 24 h,
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using the Dual-GloH Luciferase Assay system (Promega) according
to the manufacturer’s protocol. Light emission was determined on
a infiniteH M200 (Tecan, Switzerland) microplate reader.
Mono Mac 6 and THP-1 were transfected by electroporation
using BioRadH Gene Pulser II.
Electroporation of Mono Mac 6 was performed according to
Klan et al. [20] with some modifications. Cells were grown for 1 d,
washed with PBS pH 7.4 and resuspended in RPMI without
additives at a density of 4610
6 per ml. 300 ml of cell suspension
were transferred into a 0.4 cm electroporation cuvette (Invitrogen)
and 50 ml of plasmid solution, containing 20 mg reporter plasmid
and 1 mg pRL-SV40 (Promega) as internal control, were added.
Electroporation was conducted at 975 mF and 200 V. Cuvettes
were immediately transferred on ice for 20 minutes. Cells were
transferred into 50 ml prewarmed growth medium without phenol
red and were treated. Eight hours after treatment cells were
harvested, washed with PBS and luciferase assay was performed as
described for HeLa cells.
Minor modifications for transfection of THP-1 were applied:
Electroporation was conducted in BTXpress Electroporation
Solution at 250 V and 950 mF.
Cells were transferred into growth medium immediately after
electroporation and luciferase assay was performed 12 h after
treatment.
Western Blotting
Cells were cultivated for 24 h in charcoal-stripped FCS, treated
and harvested 24 h after treatment. Then, they were lysed with
1% Triton X-100 in PBS containing protease inhibitors (Complete
Table 1. Oligonucleotides used for cloning by PCR.
Gene Sequence of oligonucleotides used for cloning
a)
Parental
vector
Restriction
sites
Name of
target
vector
CD69 F: ATAGCTAGCACCATGAGCTCTGAAAATTGTTTCGTAGC R:
TTGAATTCCCTTATTATTTGTAAGGTTTGTTACATATCCAG
pcDNA 3.1 (+)
(Invitrogen)
NheI/EcoRI pcDNA
CD69
B2M F: CACGCTAGCTGCTGTCTCCATGTTTGATGTATCT R: GACGAATTCTCTCTGCTCCCCACCTCTAAGT pcDNA 3.1 (+)
(Invitrogen)
NheI/EcoRI pcDNA
B2M
CD69 F: CTTGCTAGCCAGAGAACAGCTCTTTGCATCCG R: CTCGAATTCCTCACTTCCTTCCCTAACAACCATTAG pcDNA 3.1 (+)
(Invitrogen)
NheI/EcoRI pcDNA
Exon 1-
Intron 1
CD69 F: GTTGCTAGCCTGGAACCCACGGGTCACTGG R: GACGAATTCTGGAAGCCGCCTTTGCTACC pcDNA 3.1 (+)
(Invitrogen)
NheI/EcoRI pcDNA
Intron 1
CD69 F: TGCTAGCGCATAGCAAGGAAGTTCCAGACCAC R:
GTCCATGGCTTTATTCTCAAGATTCCCTAGTTAATCTCAGG
pGL3-Basic
(Promega)
NheI/NcoI pGL3-
CD69
0.650
CD69 F: TGCTAGCCGTGTACCAAACTGTCACTCCCTTCC R:
GTCCATGGCTTTATTCTCAAGATTCCCTAGTTAATCTCAGG
pGL3-Basic
(Promega)
NheI/NcoI pGL3-
CD69
2.26
Luciferase; CD69 F: CGTTCGTCACATCTCATCTACCTC R: CTGCTGCAGATTACACGGCGATCTTTCCGCC; F:
GACCTGCAGTAAGGAAACATGTTCACTTATTGACTATTATAG R:
GAGTCTAGAGTGTTTATTCTACTTTTATTTCACATATATAAAAAC
pGL3-Promoter
(Promega)
SphI/XbaI in
the vector and
PstI between
the
inserts
pGL3-
Prom
CD69
3UTR
a)F= forward, R= reverse; non-genomic sequences (overhangs, restriction sites, Kozak sequence) are underline.
doi:10.1371/journal.pone.0064635.t001
Table 2. Oligonucleotides used for RT-qPCR.
Gene Sequence of oligonucleotide used for RT-qPCR
a)
CD69 (Ex1/2-2) F: GTGGACAAGAAAATGATGCC
R: CATTCATTACAGCACACAG
CD69 (Ex4/5-Ex5/39UTR) F: ACAACTGGTTCAACGTTACAGG
R: AGCAGCATCCACTGACACAG
CD69 (Intron 1) F: CTGGAACCCACGGGTCACTGG R: TGGAAGCCGCCTTTGCTACC
CD69 (Exon 1- Intron 1) F: CAGAGAACAGCTCTTTGCATCCG R: CTCACTTCCTTCCCTAACAACCATTAG
B2M F: TGCTGTCTCCATGTTTGATGTATCT
R: TCTCTGCTCCCCACCTCTAAGT
5-LO F: GAATTACTCCAAAGCGATGG
R: ATGACCCGCTCAGAAATAGTG
Smad3 F: GGCTGGAAGAAGGGCGAGCAG
R: CAGGGACCTGGGGATGGTGATGC
a)F= forward, R= reverse.
doi:10.1371/journal.pone.0064635.t002
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frozen at 280uC, thawed, homogenized (20 G needle) and
centrifuged at 10000 g, 4uC for 10 minutes. Protein concentra-
tions were determined with the PierceH BCA Protein Assay Kit
(Thermo Scientific, Rockford, USA). Readout was performed at
562 nm with an infiniteH M200 (Tecan, Switzerland) microplate
reader. Samples containing equal amounts of protein were mixed
with loading buffer (250 mM Tris-HCl, pH 6.8, 5 mM EDTA,
50% glycerol, 10% SDS, 0.05% bromphenol blue; 10% mercap-
toethanol added immediately prior use), heated at 99uC for
5 minutes and loaded onto 10 or 12% SDS polyacrylamide gels.
Gels were blotted on nitrocellulose membranes (Hybond
TM-C
extra, Amersham). Membranes were blocked in a mixture of
PBS:Odyssey Blocking buffer (Li-Cor Biosciences) (1:1) for 1.5 h at
room temperature or over night at 4uC. Afterwards, membranes
were incubated with primary antibodies (Smad3, Abcam; Actin (I-
19), Santa Cruz; p38a (C-20), Santa Cruz; Phospho-p38 MAP
Kinase (Thr180/Tyr 182), Cell Signalling) dissolved in PBS:Block-
ing buffer (1:1) containing 0.1% Tween 20. Membranes were
washed three times with PBS/0.1% Tween 20 and once with PBS
alone. Membranes were incubated with secondary antibody
(IRdye conjugated Antibodies, Li-Cor Biosciences), washed (see
above) and scanned with the OdysseyH infrared imager (Li-Cor
Biosciences). Immunoreactive proteins were quantified using
Odyssey software (Li-Cor Biosciences) and normalized to actin
(Smad3) or p38 (phospho-p38) intensity.
Lentiviral gene silencing
293T cells were seeded in 24-well plates at a density of 6610
4
cells per well. After 24 h, cells were transfected using the calcium
phosphate method. Transfection mixes contained 10 mgo f
MISSIONH shRNA TRCN0000330056 plasmid with pLKO.1 –
puro backbone (Sigma Aldrich) plus 6.5 mg and 3.5 mg of the
packaging plasmids pCMVdR8.91 [21] and pMD2.G (www.
tronolab.epfl.ch), respectively. Both packaging plasmids were
kindly provided by Dr. Manuel Grez, Georg-Speyer-Haus,
Frankfurt, Germany. Four hours after transfection, medium was
replaced with 1 ml THP-1 growth medium. Virus production was
allowed for 72 h. Then, the supernatant of transfected cells was
collected and filtered trough a 0.22 mm filter (Roth, Karlsruhe).
Four hours prior to transduction, THP-1 cells were seeded in 24-
well plates in growth medium containing protaminsulfate (4 mg/
ml, Calbiochem). Each well contained 3 6 10
5 cells in 0.5 ml
medium. Six wells were treated with 50 ml of 293T supernatant,
respectively. Supernatant of untransfected 293T was used as
control for selection. In order to obtain a negative control cell line,
5 ml Mission non Target shRNA control transduction particles
(Sigma Aldrich) were used per well. Plates were centrifuged for
90 minutes at 10006g, 32uC. Subsequently, medium was added
to a final volume of 1 ml in each well and cells were incubated at
37uC, 5% CO2 for 3 days.
After incubation, cells from each 6 wells were pooled, counted,
washed with PBS pH 7.4 and seeded in fresh medium with
1.5 mg/ml puromycin at a density of 3610
5 cells/ml. After two
weeks of puromycin selection, cells were used for experiments.
Reagents
PMA, JNK-Inhibitor XI, (5Z)-7-oxozeaenol and (5Z)-zeaenol
were obtained from Calbiochem. 1a,25(OH)2D3, cycloheximide,
actinomycin D, calphostin C, staurosporine, SB431542 and
U0126 were purchased from Sigma-Aldrich. SB203580 and
PD98059 were purchased from Enzo Life Sciences. Human
TGF-b was purified according to Werz et al. 1996 [22].
Statistics
Data are presented as mean + standard deviation (SD), derived
from a minimum of three independent experiments. Statistical
analysis was conducted using the software Graph Pad Prism,
version 5.0 (GraphPad Software, San Diego, California, USA).
Significance of differences between two groups was analyzed using
two tailed, unpaired t-tests. Data expressed as fold changes relative
to a reference group were analyzed using one sample t-tests.
Analysis of variance (ANOVA) was performed for significance
analysis of more than two groups, combined with multi
comparison post tests (Dunnett’s or Bonferroni’s, as indicated in
the respective figure legends).
Results
CD69 mRNA expression is induced by TGF-b/
1a,25(OH)2D3 in monocytic cells but not in T- or B-cells
Human monocytic cell lines (THP-1 and Mono Mac 6), T-cells
(Jurkat) and B-cells (Rec-1) were treated with TGF-b/
1a,25(OH)2D3 for 24 h, and absolute CD69 mRNA levels were
determined by RT-qPCR. Almost no CD69 mRNA was detected
in untreated THP-1 cells, but mRNA levels could be markedly
raised to ,800 mRNA copies per 10
6 copies beta-2 microglobulin
(B2M) mRNA by treatment with TGF-b/1a,25(OH)2D3. Slightly
higher absolute mRNA levels (,1300 copies per 10
6 copies B2M)
were obtained in TGF-b/1a,25(OH)2D3 treated Mono Mac 6
cells, starting from a basal mRNA level of 520 molecules CD69
mRNA per 10
6 B2M, thus resulting in a 2.5-fold increase (Fig. 1A).
In contrast, no induction of CD69 mRNA was found in Jurkat or
Rec-1 cells, but the basal levels of ,22.000 (Jurkat) and ,27.000
(Rec-1) CD69 mRNA molecules per 10
6 B2M, were considerably
higher in these cell lines (Fig. 1B).
Induction of CD69 mRNA expression by TGF-b/
1a,25(OH)2D3 occurs rapidly and in a concentration
dependent manner
To examine the concentration dependence of CD69 mRNA
induction, THP-1 cells were either treated with TGF-b 1 ng/ml in
combination with 1a,25(OH)2D3 in concentrations between 50
pM and 50 nM, or conversely with 50 nM 1a,25(OH)2D3 and
TGF-b in varying concentrations from 1 pg/ml to 1 ng/ml. This
was compared with single TGF-b (1 ng/ml) or 1a,25(OH)2D3
(50 nM) treatments, or with untreated controls (Fig. 2A). Neither
TGF-b nor 1a,25(OH)2D3 alone induced CD69 mRNA expres-
sion. For the combination of TGF-b and 1a,25(OH)2D3, a TGF-b
concentration of 0.1 ng/ml or higher was required to induce
CD69 mRNA expression together with 1a,25(OH)2D3. When
different concentrations of 1a,25(OH)2D3 were combined with
TGF-b 1 ng/ml, 1a,25(OH)2D3 acted concentration dependently.
In contrast, the presence of TGF-b was not a prerequisite for 5-
lipoxygenase mRNA induction by 1a,25(OH)2D3,a s
1a,25(OH)2D3 alone led to a 7.5-fold increase in mRNA
expression (Fig. 2B). As observed for CD69, 1a,25(OH)2D3 also
acted concentration dependently on 5-LO mRNA expression in
presence of TGF-b in a concentration of 1 ng/ml.
In order to analyze the time course of CD69 mRNA induction,
THP-1 cells were treated with TGF-b 1 ng/ml in combination
with 1a,25(OH)2D3 50 nM for 2, 8, 24 or 48 h. CD69 mRNA
abundance was analyzed by RT-qPCR using two primer pairs.
Alongside the primer pair specific to the proximal part (exon 1/2-
2), which was used for the initial results (Fig. 1–Fig. 2B), an
additional primer pair binding to the distal (exon 4/5-5/39UTR)
region of the CD69 gene was employed (Fig. 3A). In comparison
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CD69 mRNA expression was induced rapidly, rising from
undetectable levels to 250 mRNA copies per 10
6 B2M mRNAs
after 2 h (Fig. 3B). The increase in expression continued almost
linearly up to 24 h and reached a plateau afterwards. In contrast,
5-lipoxygenase gene induction was not detectable before 2 h after
treatment (Fig. 3D). For transcripts comprising the distal part of
the CD69 gene, a basal level of 270 mRNA copies per 10
6 B2M
was detected in untreated cells, which was raised exactly in parallel
with the transcripts including the proximal part. In addition,
primary CD69 transcripts were quantified using a primer pair
specific for the sequence around the junction of exon 1 and intron
1 and one encompassing the first intron of the CD69 gene. The
kinetics of the increase in nascent pre-mRNA copy numbers
(Fig. 3C) correlated with the increase in mature RNA species
(Fig. 3B) with the ratio between the two species averaging at 1:5.
Taken together, the rapid onset of CD69 mRNA induction by
TGF-b/1a,25(OH)2D3, where primary and mature transcripts rise
in parallel, indicates that CD69 is a primary TGF-b/
1a,25(OH)2D3 target gene in monocytic cells that is regulated
on the level of transcriptional activation by the combination of
these compounds.
Simultaneous presence of TGF-b and 1a,25(OH)2D3 is
required for CD69 and 5-LO mRNA induction
In order to investigate whether induction of CD69 and 5-LO
mRNA by TGF-b and 1a,25(OH)2D3 requires the simultaneous
presence of both agents, or if one of the agents alone was capable
of priming the cells for the action of the other, we performed
sequential treatments. For this, we treated THP-1 with either
agent alone for 12 h, exchanged medium and incubated with the
respective other compound for another 24 h. As controls, we used
cells treated with TGF-b/1a,25(OH)2D3 for 24 h and untreated
cells. We found that pre-treatment with neither of the compounds
induced mRNA levels to the same extent as simultaneous
incubation (Fig. 4). For the CD69 gene, only pre-treatment with
1a,25(OH)2D3 followed by TGF-b treatment led to modestly
enhanced mRNA levels compared to untreated control (Fig. 4A).
In contrast, levels of 5-LO mRNA were increased moderately in
both ways of pre-treatment as compared to untreated cells
(Fig. 4B), however the extent of induction was only slightly higher
than that obtained by incubation with the single compounds as
observed in the concentration series (Fig. 2B). Thus, combined
treatment is necessary for strong induction of both mRNA species
and pre-treatment more or less reflects the setting of single
treatment.
CD69 promoter fragments are not responsive for
activation by TGF-b/1a,25(OH)2D3
We analyzed activation of the CD69 promoter region by TGF-
b/1a,25(OH)2D3 in HeLa, THP-1 and Mono Mac 6 cells using
transient reporter gene assays. The CD69 promoter constructs
comprised 20.65 to +0.08 or 22.26 to +0.08 kb of the promoter
region (relative to the transcription start site) in front of the
luciferase reporter gene. These regions have been characterized as
the most responsive parts of the CD69 promoter to PMA
activation [23]. Transfected cells were treated with TGF-b/
1a,25(OH)2D3 for 24 h before luciferase activation. No induction
by TGF-b/1a,25(OH)2D3 was detected for the CD69 promoter
constructs in HeLa cells, whereas PMA activated both fragments
approximately 8-fold. Reporter constructs serving as positive
control for TGF-b mediated promoter activation via Smads
(pGL3-Basic-(CAGA)12-MLP-Luc) or containing vitamin D re-
sponse elements (p(DR3)4tk luc) were activated 3-fold and 2-fold
Figure 1. Influence of TGF-b/1a,25(OH)2D3 on CD69 mRNA expression in different cell types. (A and B) Cells were treated with 1 ng/ml
TGF-b and 50 nM 1a,25(OH)2D3 (TV) for 24 h or left untreated as control (w/o). Subsequently, mRNA levels were determined by qPCR. Statistical
analysis was conducted with two tailed, unpaired t-test (*P,0.05; **P,0.01; #P=0.0638).
doi:10.1371/journal.pone.0064635.g001
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positive control construct p3TP-Lux, which contains adjacent
SBEs and TPA/PMA responsive elements (TREs), was activated
3-fold by TGF-b/1a,25(OH)2D3 and 7-fold by PMA (Fig. 5A).
Next, the reporter constructs were either cotransfected with
expression vectors encoding the transcription factors vitamin D
receptor (VDR), retinoid X receptor (RXR), Smad3 and Smad4,
or with empty vectors. Luciferase activity was increased for all
Figure 2. Concentration dependence of CD69 and 5-LO mRNA induction by TGF-b/1a,25(OH)2D3. (A and B) Cells were treated with
varying concentrations of TGF-b and 1a,25(OH)2D3 and mRNA levels were determined by qPCR. Concentrations, as indicated after ‘‘T’’ for TGF-b and
‘‘V’’ for 1a,25(OH)2D3, are presented in ng/ml and nM, respectively. The insert in (B) shows fold inductions of 5-LO mRNA over untreated control. One
way ANOVA was performed with Dunnett’s multiple comparison post test(*P,0.05; ***P,0.001). Fold induction of 5-LO was analyzed with one
sample t-test.
doi:10.1371/journal.pone.0064635.g002
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CD69 mRNA (exon and intron sizes are not to scale). (B, C and D) Cells were treated for 2, 8, 24 and 48 h with (TV) or without (w/o) TGF-b/
1a,25(OH)2D3 (1 ng/ml and 50 nM, respectively) and mRNA levels were determined by qPCR. Statistical analysis was done by two way ANOVA and
Bonferroni’s post test (*P,0.05; **P,0.01; ***P,0.001). The two parts of CD69 gene were analyzed independently. In (B and C), significances as
determined by the Bonferroni post test on the data for each part of the gene, compared with the corresponding untreated control, are displayed.
doi:10.1371/journal.pone.0064635.g003
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inducibility of the control constructs for (1a,25(OH)2D3) and TGF-
b response increased dramatically, but induction of CD69
promoter constructs by TGF-b/1a,25(OH)2D3 was still not
detectable (Fig. 5B). Similarly, CD69 promoter constructs did
not respond when THP-1 and Mono Mac 6 as monocytic cells
were transfected (Fig. 5C).
From this, we concluded that (1) regulatory elements located
outside the CD69 proximal promoter regions might be responsible
or needed additionally in order to activate CD69 mRNA
transcription (2) complex chromatin remodelling events, that can
not be properly reproduced in transient reporter assays might be
involved in TGF-b/1a,25(OH)2D3 action, or (3) that TGF-b/
1a,25(OH)2D3 treatment acts on CD69 mRNA stability.
CD69 mRNA stability is not influenced by TGF-b/
1a,25(OH)2D3
In order to assess whether the combination of TGF-b and
1a,25(OH)2D3 acts on CD69 mRNA stability, qRT-PCR analysis
was carried out after incubation with the transcription inhibitor
actinomycin D. As THP-1 cells were not suitable for this approach
due to their lack of basal CD69 mRNA expression, Mono Mac 6
cells were used. Mono Mac 6 cells were preincubated with TGF-
b/1a,25(OH)2D3 or left untreated for 24 h. Then 1 mg/ml
actinomycin D was added and CD69 mRNA level was analyzed
at the indicated time points. CD69 mRNA half life was
comparable (less than 2 h) between treated and untreated samples
(Fig. 6A).
The 39UTR region of the CD69 gene is known to contain
destabilizing AU-rich elements [24], and stabilization of mRNAs
containing AU-rich elements by TGF-b has been shown [25].
Therefore, we inserted the CD69 39UTR into a SV40-promoter
driven luciferase reporter vector and analyzed changes in relative
luciferase activity as compared to the empty vector with or without
TGF-b/1a,25(OH)2D3 treatment. As expected, insertion of the
CD69 39UTR decreased luciferase activity 5.8-fold, but this effect
could not be reverted by TGF-b/1a,25(OH)2D3 (Fig. 6B).
Thus, the stability of CD69 mRNA is not influenced by TGF-
b/1a,25(OH)2D3 treatment.
Induction of CD69 mRNA expression by TGF-b/
1a,25(OH)2D3 depends on Smad3
Next, we analyzed whether TGF-b contributes to mRNA
upregulation via the classical Smad pathway. For this purpose, we
employed lentiviral shRNA for functional knockdown of Smad3
expression in THP-1 cells. At first, five independent shRNA
constructs were analyzed for Smad3 mRNA reduction by transient
transfection of 293T cells, and the most effective construct was
subsequently used to generate a stable cell line (data not shown). A
negative control cell line was established using non target shRNA.
The Smad3 shRNA construct led to a 37% and 73% reduction in
mRNA and protein level, respectively, compared to untransduced
cells (Fig. 7A and B).
The cells were incubated with TGF-b/1a,25(OH)2D3 for 24 h,
and CD69 and 5-LO mRNA levels were analyzed by RT-qPCR.
Smad knockdown resulted in a 71% decrease of CD69 mRNA
induction by TGF-b/1a,25(OH)2D3. In contrast, induction of 5-
LO mRNA was not altered significantly (Fig. 7C). Therefore, we
clearly demonstrate that CD69 mRNA induction by TGF-b/
1a,25(OH)2D3 depends on Smad3, whereas 5-LO upregulation
seems to be independent of Smad3.
Induction of CD69 mRNA expression by TGF-b/
1a,25(OH)2D3 is mediated by the TGF-b receptor and is
blocked by inhibitors of the MAPK pathway
In order to dissect the mechanism of TGF-b/1a,25(OH)2D3 on
CD69 and 5-LO gene expression in more detail, THP-1 cells were
treated with TGF-b/1a,25(OH)2D3 for 24 h in presence or
absence of different inhibitors before CD69 or 5-LO mRNA levels
were determined. The inhibitors were directed against proteins
that are either implicated in TGF-b signalling (TGF-b receptor I;
p38 MAPK, Mek/Erk and Jnk; TGF-b activated kinase) or can be
connected to CD69 promoter activation (PKC). The MAPK
pathways p38 MAPK, Mek/Erk, Jnk and TGF-b activated kinase
Figure 4. Effects of sequential treatment with TGF-b and 1a,25(OH)2D3. (A and B) THP-1 were treated with (TV) or without (w/o) 1 ng/ml
TGF-b and 50 nM 1a,25(OH)2D3 for 24 h or pretreated for 12 h with either 1 ng/ml TGF-b (T12h V24h) or 50 nM 1a,25(OH)2D3 (V12h T24h), washed
with PBS and subsequently treated with the respective other compound for another 24 h. CD69 and 5-LO mRNA levels were determined by qPCR.
Statistical analysis was conducted with one way ANOVA and Bonferroni’s post test (*P,0.05).
doi:10.1371/journal.pone.0064635.g004
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[11,12], and PKC inhibitors were employed due to the fact that
the proximal CD69 promoter is known to contain AP1 binding
sites [26] and is responsive to phorbol ester stimulation [23].
Moreover, AP1 is a known interaction partner of activated
Smad3/4 as TGF-b effector proteins [27].
We found that the TGF-b I receptor kinase antagonist
SB431542 completely blocked CD69 mRNA induction by TGF-
b/1a,25(OH)2D3 and inhibited 5-LO mRNA induction by 78%,
which clearly shows that TGF-b/1a,25(OH)2D3 completely
(CD69) or mainly (5-LO) act via specific, receptor-mediated
effects (Fig. 8A). The increase in proximal CD69 mRNA was
diminished after treatment with inhibitors against the three major
MAPK pathways p38 MAPK (SB203580), Erk (PD98059, U0126)
and Jnk (Jnk Inhibitor XI), by 78%, 44–66% and 85%,
respectively. In contrast, 5-lipoxygenase induction was only
Figure 5. Reporter gene analysis of the proximal CD69 promoter. (A) HeLa cells were transfected with the indicated reporter plasmids and
treated with or without 1 ng/ml TGF-b and 50 nM 1a,25(OH)2D3 (TV) or 15 ng/ml phorbol 12-myristate 13-acetate (PMA). Luciferase activity was
measured 24 h after treatment as described under ‘‘Materials and Methods’’. The values are expressed as fold induction over untreated cells.
Statistical analysis was performed with one sample t-test (*P,0.05; #=0.0538). (B) HeLa cells were transfected with the indicated reporter plasmids
and expression vectors encoding human vitamin D receptor (VDR), retinoid X receptor (RXR), Smad3 and Smad4 or the corresponding empty vectors.
Cells were either treated with 1 ng/ml TGF-b and 50 nM 1a,25(OH)2D3 (TV) or left untreated (w/o). Luciferase activity was measured 24 h after
treatment. The values are expressed as fold inductions over untreated cells cotransfected with empty vectors. Statistical analysis was conducted with
one sample t-test (*P,0.05; ***P,0.001). (C) THP-1 or Mono Mac 6 cells were transfected with the indicated reporter plasmids and were treated with
or without 1 ng/ml TGF-b and 50 nM 1a,25(OH)2D3 (TV). After 12 h (THP-1) and 8 h (Mono Mac 6), luciferase assay was performed. The values are
expressed as fold induction over untreated cells.
doi:10.1371/journal.pone.0064635.g005
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and Erk inhibition had only little effects (Fig. 8B). Inhibition of
TGF-b activated kinase 1 (TAK1) led to a 80% decrease of CD69
mRNA induction, as compared to 31% for the 5-LO gene.
Zeaenol, which served as negative control compound for the
selective TAK1 inhibitor Oxozeaenol, did not significantly change
CD69 or 5-LO mRNA expression (Fig. 8C).
With the PKC inhibitors calphostin C and staurosporine, we
found that neither calphostin C at 0.1 or 0.2 mM nor staurosporine
10 nM potently blocked CD69 mRNA induction, only at 100 nM
staurosporine a 60 and 78% reduction was detectable for proximal
and distal parts of CD69 mRNA, respectively. 5-LO mRNA
abundance was not affected by both inhibitors (Fig. 8D).
Taken together, TGF-b/1a,25(OH)2D3 act differently on CD69
and 5-LO mRNA regulation regarding the involvement of the
MAPK pathway, with inhibition being prominently detected for
the CD69 gene. It is unlikely that PKC plays a major role in the
regulation of CD69 gene expression by TGF-b/1a,25(OH)2D3 in
monocytic cells.
TGF-b/1a,25(OH)2D3 induce p38 phosphorylation that is
blocked by TAK1 inhibition
Our inhibitor studies revealed that inhibitors of TAK1 and p38
MAPK reduced CD69 mRNA induction to exactly the same
extent (Fig. 8B–C). This is in line with findings that activation of
p38 by TGF-b is mediated by TAK1 in HEK293 cells [28].
Therefore, we first analyzed whether TGF-b/1a,25(OH)2D3
activate p38 MAPK by phosphorylation in THP-1 cells. Interest-
ingly, we found that only the combination of TGF-b and
1a,25(OH)2D3, but not the single compounds, led to prominent
p38 phosphorylation (Fig. 9A). Subsequently, we tested whether
TAK1 inhibition abrogates p38 phosphorylation using the TAK1
inhibitor oxozeaenol and the control compound zeaenol in TGF-
b/1a,25(OH)2D3 treated THP-1 cells. Oxozeaenol almost com-
pletely inhibited p38 phosphorylation, whereas zeaenol had no
effect on the phosphorylation status (Fig. 9B).
These findings show that TGF-b/1a,25(OH)2D3 cooperatively
induce TAK1-mediated p38 phosphorylation.
Combined effects of TGF-b/1a,25(OH)2D3 and PMA on
CD69 mRNA induction revert over time
In lymphocytes, CD69 expression has been studied extensively,
and it is well known that the almost undetectable CD69 mRNA
levels in these cells are induced strongly upon PMA treatment
[23,29,30,31]. We determined absolute CD69 mRNA levels in
PMA treated Jurkat, MOLT-4 and Rec-1 cells and observed
several hundred-fold higher mRNA levels compared to those in
TGF-b/1a,25(OH)2D3 treated monocytic cells (Fig. 10A; Fig. 1A).
Analogously, PMA treatment of monocytic cells led to significantly
lower CD69 mRNA levels than in equally stimulated lymphocytes
(Fig. 10B). In Mono Mac 6 cells, CD69 mRNA levels were slightly
higher after PMA treatment compared to incubation with TGF-b
and 1a,25(OH)2D3, whereas in THP-1 cells TGF-b/
1a,25(OH)2D3 treatment led to 4.8 fold higher CD69 mRNA
levels than PMA treatment (Fig. 10B; Fig. 1A).
We investigated the possibility that TGF-b/1a,25(OH)2D3 act
on the CD69 gene locus of monocytic cells by converting the
chromatin architecture into a permissive state and therefore prime
cells for PMA response. To elucidate this, we treated THP-1 cells
with TGF-b/1a,25(OH)2D3 or PMA alone for 48 h, or cells were
sequentially incubated with or without TGF-b/1a,25(OH)2D3 for
24 h, and PMA was added for further 24 h.
Unexpectedly, instead of acting cooperatively, PMA efficiently
inhibited CD69 mRNA induction by TGF-b/1a,25(OH)2D3 in
this setting (Fig. 10C).
For further analysis, we performed a time course experiment
with combined treatment of TGF-b/1a,25(OH)2D3 and PMA, as
well as either treatment alone, or no treatment (Fig. 10D).
Remarkably, we observed a strong synergism of TGF-b/
1a,25(OH)2D3 and PMA after 2 and 4 h, whereas PMA abolished
the effect of TGF-b/1a,25(OH)2D3 after 12 and 24 h of
treatment.
Figure 6. Influence of TGF-b/1a,25(OH)2D3 on CD69 mRNA half
life. (A) Cells were treated with 1 ng/ml TGF-b and 50 nM 1a,25(OH)2D3
(TV) for 24 h or left untreated as control (w/o). Then 1 mg/ml
actinomycin D was added to both treatment groups and cells were
harvested at the indicated time points after actinomycin D treatment.
Subsequently, mRNA levels were determined by qPCR. Data are
expressed relative to time zero (immediately before addition of
actinomycin D) (B) HeLa cells were transfected with the indicated
reporter plasmids and expression vectors encoding human vitamin D
receptor (VDR), retinoid X receptor (RXR), Smad3 and Smad4 or the
corresponding empty vectors. Cells were either treated with 1 ng/ml
TGF-b and 50 nM 1a,25(OH)2D3 (TV) or left untreated (w/o). Luciferase
activity was measured 24 h after treatment. The data are presented as
relative luminescence units (RLU, luciferase activity of reporter plasmid
normalized to the luciferase activity of the internal standard plasmid).
doi:10.1371/journal.pone.0064635.g006
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CD69 has been functionally linked to 5-lipoxygenase, the key
enzyme in leukotriene biosynthesis, in a study with CD14-positive
monocytes [3]. Both CD14 and 5-lipoxygenase are known target
genes for TGF-b and 1a,25(OH)2D3 in this cell type [7,8,32,33].
In contrast, at present no data are available on the mechanism of
CD69 gene regulation in monocytic cells.
Figure 7. Effects of Smad3 gene silencing on CD69 and 5-LO gene regulation by TGF-b/1a,25(OH)2D3. (A) Smad3 mRNA copy numbers
of untransduced THP-1, THP-1 transduced with shRNA against Smad 3 and THP-1 transduced with non target shRNA were determined by qPCR. Smad
3 mRNA levels are displayed relative to untransduced THP-1 cells. (B) Western Blot analysis of Smad3 protein in untransduced THP-1, THP-1
transduced with shRNA against Smad3 and THP-1 transduced with non target shRNA. Protein level is displayed relative to untransduced THP-1. (C)
qPCR analysis of CD69 and 5-LO mRNA levels in untransduced THP-1, THP-1 transduced with shRNA against Smad3 and THP-1 transduced with non
target shRNA with and without treatment with 1 ng/ml TGF-b and 50 nM 1a,25(OH)2D3 (TV) for 24 h, respectively. Results are presented relative to
treated untransduced THP-1. For statistical analysis of (A), (B) and (C) one sample t test was used (*P,0.05; **P,0.01; ***P,0.001).
doi:10.1371/journal.pone.0064635.g007
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1a,25(OH)2D3 target gene and is therefore coexpressed with 5-
lipoxygenase, but that individual mechanisms account for TGF-b/
1a,25(OH)2D3 action regarding the two genes.
We could find that CD69 mRNA upregulation by TGF-b/
1a,25(OH)2D3 occurs cell-specifically in monocytes, but not in T-
or B-cells. This expression pattern conforms to the 5-LO gene,
where TGF-b/1a,25(OH)2D3 do not induce expression in T- and
B-cells either (Dieter Steinhilber, unpublished data). It must
however be noted as a difference between the two genes that T-
cells do express CD69 upon cellular activation by different
signalling molecules [29], but are 5-LO negative cells [34]. The
similarities in the expression pattern could indicate that the
proteins have a monocyte-specific functional relationship.
The two monocytic cell lines THP-1 and Mono Mac 6 differed
in the occurrence of basal CD69 mRNA expression; no CD69
mRNA could be detected in untreated THP-1 cells whereas Mono
Mac 6 cells exhibited a basal level of CD69 mRNA. It has been
Figure 8. Inhibitor studies on signalling mechanisms of TGF-b/1a,25(OH)2D3-mediated CD69 and 5-LO gene regulation. (A–D) THP-1
cells were treated with 1 ng/ml TGF-b and 50 nM 1a,25(OH)2D3 (TV) or left untreated (w/o) for 24 h after 30 min pre-incubation with or without the
indicated inhibitors. Inhibitor concentrations used were as follows: SB431542 10 mM, PD98059 50 mM, U0126 10 mM, SB203580 10 mM, JNK-Inhibitor
XI 10 mM as well as oxozeaenol and zeaenol 0.3 mM, respectively. Applied concentrations for calphostin C (CalC) and staurosporine (STS) are indicated.
Levels of mRNA are presented relative to the corresponding values after TGF-b/1a,25(OH)2D3 treatment. Statistical analysis was conducted with one
sample t test (*P,0.05; **P,0.01; ***P,0.001).
doi:10.1371/journal.pone.0064635.g008
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status, with Mono Mac 6 being more differentiated towards
mature monocytes than THP-1 [35]. Therefore, a basal level of
CD69 expression is possibly acquired during monocyte matura-
tion.
We observed marked differences regarding CD69 and 5-
lipoxygenase mRNA induction by TGF-b/1a,25(OH)2D3.I n
both cases, the combination of TGF-b and 1a,25(OH)2D3 was
required for the maximum effect, but in case of 5-LO also
1a,25(OH)2D3 alone was sufficient to induce mRNA expression,
whereas CD69 expression strictly depends on the presence of
TGF-b (Fig. 2A and B). This is also reflected by the results of
sequential treatment (Fig. 4). The results show that cooperation
between TGF-b/1a,25(OH)2D3 depends on simultaneous pres-
ence of both agents and neither of the agents alone is capable of
priming for the full effect. Therefore, for both genes, combined
action of TGF-b and 1a,25(OH)2D3 is rather a primary than a
secondary effect. Furthermore, we detected kinetic differences
between the two genes. CD69 mRNA abundance was induced
within 2 h, and thus increased more rapidly than 5-LO mRNA
levels, where a significant induction could only be observed later
than 2 h. The rapid onset of CD69 mRNA induction also suggests
that CD69 is a primary TGF-b/1a,25(OH)2D3 target gene.
Methodologically, primary and secondary target genes are often
distinguished by the use of protein synthesis inhibitors like
cycloheximide. However, due to the fact that the CD69 39UTR
contains destabilizing AU-rich elements [24], and such mRNAs
are known to be strongly stabilized by cycloheximide [36], this
approach was not suitable for the CD69 gene. On the other hand,
TGF-b has been shown to increase the half-life of mRNAs which
contain AU-rich elements in their 39UTRs [25,37]. Therefore, we
investigated whether CD69 mRNA induction by TGF-b/
1a,25(OH)2D3 is based on mRNA stabilization. However, neither
half life studies using the transcription inhibitor actinomycin D nor
39UTR analysis using reporter genes indicated an influence of
TGF-b/1a,25(OH)2D3 on CD69 mRNA stability. Analysis of pre-
mRNA species revealed that the combination of TGF-b and
1a,25(OH)2D3 directly activates CD69 transcription (Fig. 3C).
Regarding the quantification of mature mRNA species over time,
we observed that transcripts including the proximal (exons 1–2)
and the distal (exon 4–39UTR) part of the CD69 gene increased in
parallel upon TGF-b/1a,25(OH)2D3 treatment, however, the
number of transcripts comprising the distal part was uniformly
higher for all time points, for both treated and untreated cells
(Fig. 3B). Several reasons could possibly account for this
observation. It is conceivable that a constantly expressed transcript
comprising the distal part originates from a second gene that
overlaps with the CD69 gene, or from an alternative transcription
start site within the distal part of the CD69 gene. Moreover,
alternatively spliced transcripts lacking proximal parts, as
described for the porcine CD69 gene [38], come into consider-
ation. However, such an overlapping gene, or such transcripts,
respectively, have not been described as yet. Furthermore, slow
degradation of CD69 mRNA starting from the 59-end may render
species that only comprise the distal part.
To further analyze the mechanisms of TGF-b/1a,25(OH)2D3
action, we used (a) lentivirus-delivered stable gene silencing of
Smad3 as the central component of Smad-dependent TGF-b
signalling, (b) pharmacological inhibitors, (c) reporter gene assays
with constructs containing CD69 promoter fragments of different
length.
First, we could clearly show by stable silencing of Smad3
expression in THP-1 cells that TGF-b/1a,25(OH)2D3-mediated
CD69 induction depends on Smad3, whereas this is not the case
for 5-LO. Regarding 5-LO expression, this is in contrast to
findings that overexpression of Smads3/4 induces plasmid-based
5-lipoxygenase expression in reporter gene assays [39]. These
differences may be attributed to the fact that the reporter gene
assay was conducted in a heterologous cell system and that a
Figure 9. Western Blot analysis of p38 phosphorylation in
dependence of treatment with TGF-b and/or 1a,25(OH)2D3. (A)
Western Blot analysis of p38 protein and phosphorylated p38 protein in
THP-1 incubated for 24 h with 1 ng/ml TGF-b (T), 50 nM 1a,25(OH)2D3
(V), both agents (TV) or without treatment (w/o). The relative phospho-
p38 level (normalized to total p38 protein) of TGF-b/1a,25(OH)2D3
treated cells was set to 1. (B) THP-1 cells were treated with (TV) or
without (w/o) 1 ng/ml TGF-b and 50 nM 1a,25(OH)2D3 for 24 h after
30 min pre-incubation with or without the indicated inhibitors. Applied
concentrations of oxozeaenol and zeaenol were 0.3 mM, respectively.
Phosphorylated p38 compared to whole p38 protein was analyzed by
western blot. Relative protein amount of TGF-b/1a,25(OH)2D3 treated
cells was set to 1. Statistical analysis of (A) and (B) was done with one
sample t-test (*P,0.05; **P,0.01).
doi:10.1371/journal.pone.0064635.g009
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positive cell as it was used in our approach. Using pharmacological
inhibitors, we could clearly show for CD69 that the TGF-b/
1a,25(OH)2D3 signal completely depends on stimulation of a
specific receptor, the TGF-b receptor I. Subsequently, we used
inhibitors of TAK1 and the three major MAPK pathways p38
MAPK, Jnk and Erk. Our data reveal that the classical MAPKs
and TAK1 play a role in CD69 regulation by TGF-b/
1a,25(OH)2D3. Interestingly, TAK1 and p38 MAPK inhibition
diminished CD69 induction to the same extent, which pointed to a
Figure 10. Influence of PMA on CD69 mRNA levels in dependence of time and cotreatment. (A and B) Cells were treated with (PMA) or
without (w/o) 20 ng/ml PMA for 24 h. Subsequently, mRNA levels were determined by qPCR. Statistical analysis of (A) and (B) was conducted with
unpaired, two-tailed t-test (**P,0.01; ***P,0.001). (C) THP-1 were treated with 1 ng/ml TGF-b and 50 nM 1a,25(OH)2D3 (TV), 20 ng/ml PMA (PMA) or
left untreteated as control (w/o) for 48 h. Alternatively, cells were pretreated with (TV) or without (w/o) 1 ng/ml TGF-b and 50 nM 1a,25(OH)2D3 for
24 h and 20 ng/ml PMA was added for further 24 h. Subsequently, CD69 mRNA levels were determined by qPCR. The CD69 mRNA level of cells
treated with TGF-b/1a,25(OH)2D3 for 48 h was set to 100. Statistical analysis was conducted with one sample t-test (*P,0.05; **P,0.01; ***P,0.001).
(D) THP-1 were incubated with 1 ng/ml TGF-b and 50 nM 1a,25(OH)2D3 (TV), 20 ng/ml PMA (PMA), all three agents together (TV/PMA) or left
untreated as control (w/o) for the indicated times. Subsequently, CD69 mRNA levels were determined by qPCR.
doi:10.1371/journal.pone.0064635.g010
CD69 Is a TGFbeta/Vitamin D3 Target Gene
PLOS ONE | www.plosone.org 14 May 2013 | Volume 8 | Issue 5 | e64635direct dependence between these two kinases, as demonstrated for
TGF-b treated HEK293 cells [28]. This interplay could indeed be
confirmed by Western Blot analysis of differences in p38
phosphorylation in the presence or absence of TAK1 inhibitor.
Taken together, this suggests that TGF-b/1a,25(OH)2D3 act on
CD69 mRNA expression via TAK1-mediated p38 activation.
Regarding 5-LO regulation and MAPK involvement, we only
found 50% inhibition by the Jnk inhibitor. The 5-LO promoter
contains two AP1 response elements, at pos. 22990 to 22984
(TGTCTCA [40]) and at pos. 23246 to 23240 (TGGCTCA
[41]) from the translational start site, which could potentially be
addressed by activated c-Jun. However, no activation by TGF-b/
1a,25(OH)2D3 of 5-LO promoter fragments containing these
elements could be seen in transient reporter assays [42]. We
obtained the same negative result for CD69 promoter fragments
(Fig. 5), which contain AP1 sequences near the transcription start
site [23]. It is possible that Jnk-mediated protein activation,
classically of c-Jun, is not sufficient to address the AP1 elements in
the promoters without activation of interacting proteins like c-fos,
which is not a Jnk substrate [43]. Jnk might therefore act
posttranscriptionally on CD69 and 5-LO mRNA expression. It is
also possible that further proteins are needed in the multiprotein
complex interacting with the general transcriptional machinery
that are not present under the circumstances of transient reporter
assays.
The reporter constructs that were used to analyze the effect of
TGF-b/1a,25(OH)2D3 on the CD69 promoter included the
sequences between positions 20.65 to +0.08 kb and 22.26 to
+0.08 kb of the CD69 gene (relative to the transcription start site),
respectively. The shorter construct contains two putative vitamin
D response elements and two additional potential VDREs are
located in the longer construct, as predicted by the in silico
promoter analysis program ‘‘NHR Scan’’ [44]. Five putative
Smad binding elements (SBE) are located in the shorter construct
and two additional sites can be found in the 22.26 kb construct,
when the sequence is analyzed using the SBE consensus sequence
CAGAC, as postulated by Qin et al. [45].
The fact that the constructs comprising proximal promoter
regions were not responsive to 1a,25(OH)2D3 is in line with recent
findings on other 1a,25(OH)2D3 target genes, for which it was
shown that results from assays using proximal promoter constructs
were only modest or difficult to interpret. It has been put forward
that multiple regulatory sequences, often located many kilobases
from the TSS, are needed for expression control [46]. Recent
findings on Smad action have established that Smad action
depends on cooperation with ‘‘master transcription factors’’ [47],
which are as yet undefined in monocytes and may be located at
other regions of the CD69 gene or its 59 flanking sequence.
Both, the combination of TGF-b/1a,25(OH)2D3 and PMA, are
described to induce differentiation events in cells of the monocytic
lineage [48,49]. As constitutive expression of CD69 in CD14
positive monocytes is described [3], it is possible that induction of
CD69 is a differentiational event. This is in line with the different
basal CD69 mRNA levels in Mono Mac 6 and THP-1 together
with the fact that THP-1 cells in contrast to Mono Mac 6, are
negative for the monocytic marker CD14 [50,51]. However, the
mechanisms that lead to CD69 mRNA induction by TGF-b/
1a,25(OH)2D3 and PMA seem to be diverse and synergism is
strongly dependent on the time point that is considered. In
conclusion, we show here that CD69 (mRNA) expression is cell-
specifically regulated by TGF-b/1a,25(OH)2D3 in monocytic
cells. This feature is in common with the gene encoding 5-
lipoxygenase, the key enzyme in leukotriene formation. The
parallelism supports the idea of a functional relation between the
two proteins, which needs to be examined in further studies.
Moreover, our results demonstrate that the combination of the
physiological mediators TGF-b and 1a,25(OH)2D3 act on
different genes by individual mechanisms and kinetics.
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